According to our results, the homozygote genotype AA with the highest expression in the CD147 polymorphism was combined with the HLA DRB1*1501 homozygote with the lowest expression in patients with severe CTCL, which was reflected in the therapy chosen for these patients. This evidence concerns the gene BSG and primary cutaneous T-cell non-Hodgkin lymphoma.